This page contains brief information about ipilimumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Ipilimumab is approved to treat:
- Colorectal cancer in adults and children 12 years and older. It is used with nivolumab to treat metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer that got worse after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
- Melanoma.
- It is used as adjuvant therapy in patients with melanoma in the skin and lymph nodes who have already had surgery.
- It is used in adults and children 12 years and older whose disease cannot be removed by surgery or has metastasized (spread to other parts of the body).
- Renal cell carcinoma (a type of kidney cancer) that is advanced. It is used with nivolumab in some patients with renal cell carcinoma that has not been treated.
Ipilimumab is also being studied in the treatment of other types of cancer.
More About Ipilimumab
Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.
MedlinePlus Information on Ipilimumab – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
